These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26778412)

  • 21. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
    Ferenci P; Bourgeois S; Buggisch P; Norris S; Curescu M; Larrey D; Marra F; Kleine H; Dorr P; Charafeddine M; Crown E; Bondin M; Back D; Flisiak R
    J Viral Hepat; 2019 Jun; 26(6):685-696. PubMed ID: 30739368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
    Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
    J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
    Feld JJ; Kowdley KV; Coakley E; Sigal S; Nelson DR; Crawford D; Weiland O; Aguilar H; Xiong J; Pilot-Matias T; DaSilva-Tillmann B; Larsen L; Podsadecki T; Bernstein B
    N Engl J Med; 2014 Apr; 370(17):1594-603. PubMed ID: 24720703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.
    Schnell G; Tripathi R; Beyer J; Reisch T; Krishnan P; Dekhtyar T; Irvin M; Hall C; Yu Y; Mobashery N; Redman R; Pilot-Matias T; Collins C
    J Viral Hepat; 2018 Sep; 25(9):1078-1088. PubMed ID: 29624809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
    Deeks ED
    Drugs; 2015 Jun; 75(9):1027-38. PubMed ID: 26059288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
    Schnell G; Tripathi R; Krishnan P; Beyer J; Reisch T; Irvin M; Dekhtyar T; Setze C; Rodrigues L; Alves K; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
    J Med Virol; 2018 Jan; 90(1):109-119. PubMed ID: 28842997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Zhang X; Setze C; Rodrigues L; Burroughs M; Redman R; Chayama K; Kumada H; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1106-13. PubMed ID: 26643326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
    Martinello M; Bhagani S; Gane E; Orkin C; Cooke G; Dore GJ; Petoumenos K; Applegate TL; Tu E; Marks P; Pagani N; Grebely J; Nelson M; Matthews GV
    J Viral Hepat; 2018 Oct; 25(10):1180-1188. PubMed ID: 29660224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience.
    Aygen B; Demirtürk N; Yıldız O; Çelen MK; Çelik İ; Barut Ş; Ural O; Batırel A; Mıstık R; Şimşek F; Asan A; Ersöz G; Türker N; Bilgin H; Kınıklı S; Karakeçili F; Zararsız G; Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT
    Turk J Gastroenterol; 2020 Apr; 31(4):305-317. PubMed ID: 32412901
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    Poordad F; Bennett M; Sepe TE; Cohen E; Reindollar RW; Everson G; Phillips RW; Siddique A; Sullivan JG; Pilot-Matias T; Abunimeh M; Cohen DE; Younes Z
    J Med Virol; 2019 Jul; 91(7):1307-1312. PubMed ID: 30840774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
    Andreone P; Colombo MG; Enejosa JV; Koksal I; Ferenci P; Maieron A; Müllhaupt B; Horsmans Y; Weiland O; Reesink HW; Rodrigues L; Hu YB; Podsadecki T; Bernstein B
    Gastroenterology; 2014 Aug; 147(2):359-365.e1. PubMed ID: 24818763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
    Pockros PJ; Reddy KR; Mantry PS; Cohen E; Bennett M; Sulkowski MS; Bernstein DE; Cohen DE; Shulman NS; Wang D; Khatri A; Abunimeh M; Podsadecki T; Lawitz E
    Gastroenterology; 2016 Jun; 150(7):1590-1598. PubMed ID: 26976799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
    Rosenthal P; Narkewicz MR; Yao BB; Jolley CD; Lobritto SJ; Wen J; Molleston JP; Hsu EK; Jonas MM; Zha J; Liu L; Leung DH
    Adv Ther; 2020 Jul; 37(7):3299-3310. PubMed ID: 32451952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan.
    Krishnan P; Schnell G; Tripathi R; Beyer J; Reisch T; Dekhtyar T; Irvin M; Xie W; Fu B; Burroughs M; Redman R; Kumada H; Chayama K; Collins C; Pilot-Matias T
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29180522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.
    Loo N; Lawitz E; Alkhouri N; Wells J; Landaverde C; Coste A; Salcido R; Scott M; Poordad F
    World J Gastroenterol; 2019 May; 25(18):2229-2239. PubMed ID: 31143073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
    Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
    Poordad F; Sedghi S; Pockros PJ; Ravendhran N; Reindollar R; Lucey MR; Epstein M; Bank L; Bernstein D; Trinh R; Krishnan P; Polepally AR; Unnebrink K; Martinez M; Nelson DR
    J Viral Hepat; 2019 Aug; 26(8):1027-1030. PubMed ID: 30980576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.
    Fuchs M; Monto A; Bräu N; Charafeddine M; Schmidt W; Kozal M; Naggie S; Cheung R; Schnell G; Yu Y; Richards K; Mullally V; Cohen DE; Toro D
    J Med Virol; 2020 Dec; 92(12):3459-3464. PubMed ID: 31829433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection.
    Ng TI; Pilot-Matias T; Tripathi R; Schnell G; Krishnan P; Reisch T; Beyer J; Dekhtyar T; Irvin M; Lu L; Asatryan A; Campbell A; Yao B; Lovell S; Mensa F; Lawitz EJ; Kort J; Collins C
    Viruses; 2018 Aug; 10(9):. PubMed ID: 30154359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retreatment of patients with chronic hepatitis C, subtype 1b and cirrhosis, who failed previous direct-acting antiviral therapy including first- and second-generation NS5A inhibitors with ombitasvir/paritaprevir/ritonavir, dasabuvir + sofosbuvir + ribavirin.
    Fedorchenko SV; Martynovych T; Klimenko Z; Yanchenko V; Solianyk I
    J Viral Hepat; 2020 May; 27(5):548-551. PubMed ID: 31894886
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.